Trimel Pharmaceuticals Corporation
TSX : TRL

Trimel Pharmaceuticals Corporation

November 25, 2014 13:00 ET

Trimel Announces Issuance of Additional Patent Covering NATESTO™

TORONTO, ONTARIO--(Marketwired - Nov. 25, 2014) - Trimel Pharmaceuticals Corporation (TSX:TRL) today announced that its technology partner Mattern Pharma AG has been granted an additional United States Patent in respect of NATESTO™ and its proprietary nasal gel technology. Trimel expects one or more claims in such patent to be eligible for listing in the Food and Drug Administration (FDA) Orange Book in connection with NATESTO™. The Orange Book is the FDA's database of Approved Drug Products with Therapeutic Equivalence Evaluations.

This patent further enhances the patent protection available to NATESTO™ and should represent the fourth Orange Book-listed patent with claims covering the product until 2024.

"The issuance of this patent provides additional evidence of the innovative and differentiated value of NATESTO™", said Tom Rossi, President and Chief Executive Officer of Trimel. "This patent further strengthens our intellectual property position and provides further protection for this important product in Trimel's portfolio."

About Trimel

Trimel is a specialty pharmaceutical company involved in the sale, distribution, and development of products with a focus in men's health, women's health, and respiratory medicine. NATESTO™, a product utilizing Trimel's licensed nasal gel technology, has been approved for sale in the United States by the FDA and is licensed to an affiliate of Endo International plc for commercialization. For more information, please visit www.trimelpharmaceuticals.com.

Notice regarding forward-looking statements:

Information in this press release that is not current or historical factual information may constitute forward looking information within the meaning of securities laws. Implicit in this information are assumptions regarding our future operational results. These assumptions, although considered reasonable by the company at the time of preparation, may prove to be incorrect. Readers are cautioned that actual performance of the company is subject to a number of risks and uncertainties, including with respect to the Orange Book eligibility of the applicable claims and could differ materially from what is currently expected as set out above. For more exhaustive information on these risks and uncertainties you should refer to our annual information form dated March 5, 2014 which is available at www.sedar.com. Forward-looking information contained in this press release is based on our current estimates, expectations and projections, which we believe are reasonable as of the current date. You should not place undue importance on forward-looking information and should not rely upon this information as of any other date. While we may elect to, we are under no obligation and do not undertake to update this information at any particular time, whether as a result of new information, future events or otherwise, except as required by applicable securities law.

Contact Information